Biogen Secures Hybrozyme™ License from Alteogen for Subcutaneous Biologics, Up to $579M in Milestones
BIIB sits 67% above its 52-week low of $110.035.
Summary
Biogen has entered into a significant license agreement with Alteogen for the development and commercialization of Hybrozyme™-based subcutaneous biologics. Under the terms, Alteogen will receive $20 million upfront, an additional $10 million upon the development of a second product, and is eligible for up to $549 million in milestone payments across two products, along with royalties on net sales. Biogen also holds an option to develop a third product under the agreement. This strategic partnership is a material move for Biogen, enhancing its pipeline and potentially improving drug delivery and patient convenience for future biologics. The substantial potential milestone payments underscore the strategic importance of this technology to Biogen's long-term growth and product portfolio.
At the time of this announcement, BIIB was trading at $184.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.